The FDA Just Approved the First Cancer Virus Therapy Paired With a Checkpoint Inhibitor — and Replimune Made It

The FDA granted accelerated approval to Replimune's oncolytic virus therapy, marketed as TUDRIQEV, for use in combination with the checkpoint inhibitor nivolumab. An oncolytic virus is engineered to infect and destroy cancer cells directly while also triggering a broader immune response against the tumor — combining it with a checkpoint inhibitor, a drug class that works by releasing the brakes the immune system normally puts on itself, is a strategy that pairs two different ways of getting the immune system to attack cancer.

The approved indication is adults with unresectable advanced cutaneous melanoma whose disease progressed on a prior anti-PD-1 antibody-based regimen — in other words, patients who had already tried one immunotherapy approach and it stopped working. This is the first-ever approval of an oncolytic virus therapy combined with a checkpoint inhibitor, which matters beyond Replimune's own pipeline: several other biotech companies have been developing similar combination approaches, and until now none had an approved precedent to point to.

Wedbush responded to the approval by upgrading Replimune to Outperform from Neutral and raising its target to $19 a share from $12. The stock traded near its 52-week high of $13.90 in the days following the approval, up 14.8% over the prior week — consistent with a re-rating from clinical-trial uncertainty toward a commercial-launch story now that the drug has a cleared regulatory path to patients.